The majority of RNAs in each of our cells don’t code for any of the thousands of proteins that make up our bodies. Instead, noncoding RNAs have critical roles in many biological processes—such as gene expression—making them ideal targets for a variety of ailments, including cancers. Despite that, the first RNA-targeting therapeutic in the market was launched only five years ago, and the vast majority of all Food and Drug Administration–approved drugs target proteins.
Q&A: AI speeds up search for RNA-targeting drugs, opening new therapeutic possibilities
